Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.570
+0.080 (1.78%)
At close: Mar 6, 2026, 4:00 PM EST
4.510
-0.060 (-1.31%)
After-hours: Mar 6, 2026, 7:56 PM EST
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Taysha Gene Therapies stock have an average target of 10.56, with a low estimate of 7.00 and a high estimate of 14. The average target predicts an increase of 131.07% from the current stock price of 4.57.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Taysha Gene Therapies stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +118.82% | Mar 3, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +162.58% | Jan 6, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $8 → $11 | Buy | Maintains | $8 → $11 | +140.70% | Jan 5, 2026 |
| Citizens | Citizens | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +75.05% | Nov 5, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +162.58% | Nov 5, 2025 |
Financial Forecast
Revenue This Year
6.63M
from 8.33M
Decreased by -20.40%
Revenue Next Year
4.55M
from 6.63M
Decreased by -31.48%
EPS This Year
-0.37
from -0.36
EPS Next Year
-0.44
from -0.37
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 15.8M | 15.8M | ||||
| Avg | 6.6M | 4.5M | ||||
| Low | 3.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 89.0% | 137.4% | ||||
| Avg | -20.4% | -31.5% | ||||
| Low | -53.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.36 | -0.37 | ||||
| Avg | -0.37 | -0.44 | ||||
| Low | -0.37 | -0.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.